Phibro Animal Health

Phibro Animal Health Corp. engages in the manufacture and supply of animal health and mineral nutrition products. It operates through the following segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment develops and markets antibacterial, nutritional specialty products, and vaccines. The Mineral Nutrition segment consists of the formulations and concentrations of trace minerals such as zinc, manganese, copper, iron, and compounds. The Performance Products segment produces specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company was founded on May 11, 1946 and is headquartered in Teaneck, NJ.

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

Earnings data Q3 2026

Earnings data Q4 2026

Phibro Animal Health reports strong FY 2023 performance and projects continued growth in Animal Health segment

Phibro Animal Health delivered solid financial performance in FY 2023, with a strong outlook for FY 2024 driven by growth in the Animal Health segment.
Strategic investments in vaccines and companion animals position the company for continued expansion and margin maintenance amidst challenges.
Efforts to enhance operational efficiency and cash flow generation underscore a commitment to sustainable growth and financial strength.
Anticipated top and bottom-line growth, along with market stability, signal a positive trajectory for Phibro Animal Health in the upcoming fiscal year.

Phibro Animal Health reports mixed Q1 results amid market challenges

Phibro Animal Health's Q1 2024 performance was marked by growth in the Animal Health segment but challenges in other segments.
Efforts to manage working capital effectively and maintain a stable financial position are key strengths.
However, declines in adjusted EBITDA, revenue, and margins present hurdles that require strategic solutions.
Opportunities for growth lie in addressing challenges across segments and exploring innovative market strategies.

Phibro Animal Health reports Q2 growth, affirms guidance amid challenges

Phibro Animal Health's Q2 2024 performance reflects solid growth in net sales driven by the Animal Health segment, despite challenges in other segments.
The company's ability to manage operational challenges in Israel and maintain guidance reaffirm confidence in its strategic direction and resilience.
With positive demand trends and a new CFO onboard, Phibro Animal Health is poised to leverage opportunities for growth and operational excellence.

Phibro Animal Health reports robust Q3 performance and strategic acquisitions

Phibro Animal Health (PAHC) delivered a strong Q3 performance with notable growth in total company and Animal Health sales, supported by positive financial metrics and strategic acquisitions.
While facing integration challenges and competitive pressures, the company's strengths in market performance, financial health, and strategic guidance position it well for future growth.
Opportunities in product expansion, market diversification, and innovation present avenues for sustained growth and market leadership in the animal health industry.

Phibro Animal Health posts strong Q4 results, eyes Zoetis acquisition

Phibro Animal Health (PAHC) delivered robust financial results in Q4 2024, driven by growth in key segments and operational improvements.
The pending Zoetis MFA acquisition and successful refinancing demonstrate Phibro's strategic focus on expansion and financial strength.
While challenges in integration and regulatory approvals exist, Phibro is well-positioned to capitalize on opportunities for market expansion and sustained growth.
Investors can look forward to Phibro's continued performance and value creation as it navigates industry dynamics and executes on its strategic initiatives.

Phibro Animal Health reports stellar Q1 results and eyes growth

Phibro Animal Health delivered impressive Q1 2025 results, showcasing robust financial growth and strategic acquisitions.
While facing challenges such as margin concerns and project discontinuations, the company remains optimistic about its future prospects.
By capitalizing on opportunities in the acquired portfolio and focusing on operational excellence, Phibro aims to sustain its growth trajectory and drive shareholder value.

Phibro Animal Health reports robust Q2 performance and eyes growth

Phibro Animal Health delivered a strong performance in Q2 2025, marked by significant sales growth and improved profitability across segments.
While facing challenges in sustaining growth and addressing operational concerns, the company remains well-positioned with opportunities for expansion and market leadership.
Management's confidence in raising sales and EBITDA guidance for fiscal year 2025 underscores a positive outlook for future growth and value creation.
Investors should monitor Phibro Animal Health's strategic execution, market positioning, and ability to capitalize on emerging opportunities for long-term value.

Phibro Animal Health posts stellar 2025 results, eyes growth

Phibro Animal Health delivered strong financial results in Q4 2025 and full-year 2025, driven by robust growth in net sales and adjusted EBITDA, supported by strategic initiatives and successful acquisitions. While the company faces challenges in maintaining growth momentum and navigating market complexities, opportunities exist for Phibro to capitalize on its strengths, expand market reach, and drive innovation. Investors should monitor Phibro's execution of its guidance for fiscal year 2026, as the company aims to sustain its growth trajectory, capitalize on opportunities, and address potential challenges in the industry.

Phibro Animal Health excels in Q1 2026, focuses on innovation

Phibro Animal Health delivered robust financial performance in Q1 2026, driven by strong growth in Animal Health sales and profitability metrics. The company's strategic focus on innovation, execution, and sustainable value creation underscores its commitment to long-term success in the industry. While facing challenges in maintaining growth momentum, Phibro remains well-positioned to capitalize on market opportunities and drive future growth.

Phibro Animal Health (PAHC) posts robust Q2 results and eyes growth opportunities

Phibro Animal Health (PAHC) delivered a strong performance in Q2 2026, marked by significant sales growth and improved profitability. While facing challenges related to margins and market dynamics, the company is well-positioned to capitalize on opportunities in new product adoption, market outperformance, and sustainability initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Phibro Animal Health Corp. engages in the development, manufacture, and marketing of animal health and mineral nutrition products. It operates through the following segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment focuses on the development and marketing of medicated feed additives, nutritional specialty products, and vaccines. The Mineral Nutrition segment includes formulations and concentrations of trace minerals such as zinc, manganese, copper, iron, and compounds. The Performance Products segment is involved in the manufacture and marketing of specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company was founded on May 11, 1946 and is headquartered in Teaneck, NJ.